Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

被引：6
|
作者：
Birerdinc, Aybike [2 ]
Younossi, Zobair M. [1 ,2 ]
机构：
[1] Inova Fairfax Hosp, Dept Med & Ctr Liver Dis, Falls Church, VA USA
[2] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA 22042 USA
来源：
ANNALS OF HEPATOLOGY | 2018年 / 17卷 / 01期
关键词：
NASH; NAFLD; EWAS; UNITED-STATES; FERROPTOSIS; EPIDEMIOLOGY; FIBROSIS;
D O I：
10.5604/01.3001.0010.7530
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Non-alcoholic Fatty Liver Disease (NAFLD) and its progressive form or NASH with fibrosis, are rapidly increasing in conjunction with the growing rates of obesity and type II diabetes. Novel technologies such as epigenome-wide association studies (EWAS) may provide opportunities to get valuable insight into not only the mechanisms of disease, but to also discover potential biomarker targets with clinical relevance to disease stage.
引用
收藏
页码：11 / 13
页数：3
相关论文
共 50 条
  • [21] MicroRNAs as Mediators in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Steatohepatitis
    Becker, Philip P.
    Schmitt, Johannes
    Niesler, Beate
    Tschopp, Oliver
    Dandekar, Thomas
    Mullhaupt, Beat
    Geier, Andreas
    HEPATOLOGY, 2013, 58 : 554A - 554A
  • [22] Pathogenesis of non-alcoholic fatty liver disease
    Dowman, J. K.
    Tomlinson, J. W.
    Newsome, P. N.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2010, 103 (02) : 71 - 83
  • [23] Pathogenesis of non-alcoholic fatty liver disease
    Anty, Rodolphe
    Gual, Philippe
    PRESSE MEDICALE, 2019, 48 (12): : 1468 - 1483
  • [24] Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
    Holzner, Lorenz M. W.
    Murray, Andrew J.
    FRONTIERS IN MEDICINE, 2021, 8
  • [25] Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential
    Bedossa, Pierre
    LIVER INTERNATIONAL, 2018, 38 : 64 - 66
  • [26] Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Tincopa, Monica A.
    Loomba, Rohit
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (07): : 660 - 670
  • [27] Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
    Angelico, F.
    Burattin, M.
    Alessandri, C.
    Del Ben, M.
    Lirussi, F.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (01):
  • [28] What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas, Michael
    Imprialos, Konstantinos
    Stavropoulos, Konstantinos
    Athyros, Vasilios G.
    CURRENT VASCULAR PHARMACOLOGY, 2019, 17 (05) : 425 - 428
  • [29] The Role of Interferon Regulatory Factors in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Zhang, Chunye
    Liu, Shuai
    Yang, Ming
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (02) : 148 - 161
  • [30] Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Ahsan, Farah
    Oliveri, Federico
    Goud, Harshit K.
    Mehkari, Zainab
    Mohammed, Lubna
    Javed, Moiz
    Althwanay, Aldanah
    Rutkofsky, Ian H.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
12345